COMMUNIQUÉS West-GlobeNewswire

iTeos présentera les données précliniques d’EOS-984, premier médicament de sa catégorie ciblant l’ENT1, lors de l'édition 2024 du congrès annuel de l’Association américaine pour la recherche sur le cancer
05/03/2024
WATERTOWN, Massachusetts et GOSSELIES, Belgique, 05 mars 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), une société biopharmaceutique au stade clinique pionnière dans la découverte et le [...]
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
05/03/2024
SAN FRANCISCO and WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of [...]
LifeScience Logistics Enhances Offerings with Innovative Sampling & Dispensing Suite at Raleigh-Durham Facility
05/03/2024
New cleanroom suite adds secure and compliant pharmaceutical sampling and dispensing offering to world-class pharmaceutical storage and distribution facility in Raleigh-Durham, North Carolina. DALLAS, March 05, 2024 ( [...]
Sandoz receives FDA approval for first and only denosumab biosimilars
05/03/2024
MEDIA RELEASE Wyost ® (denosumab-bddz) and Jubbonti ® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ® * (denosumab) and Prolia ® * (denosumab) FDA approval [...]
ACTG CROI Presentations Show That Semaglutide Improves Metabolic-Associated Steatotic Liver Disease Among People Living With HIV
05/03/2024
LOS ANGELES, March 05, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced an oral presentation from its SLIM LIVER study (also known as A5371 [...]
Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up
05/03/2024
Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up Leuven, BELGIUM, 05 March – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical [...]
Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024
05/03/2024
Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024 Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing markets: [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 février 2024
05/03/2024
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 février 2024 Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Places de cotation : [...]
AMN Healthcare Sustainability & Social Impact Report Shows Industry-Leading Efforts
05/03/2024
DALLAS, March 05, 2024 (GLOBE NEWSWIRE) -- In its recently released 2023 Sustainability and Social Impact Report , AMN Healthcare (NYSE: AMN), the leader and innovator in total talent solutions for healthcare [...]
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
05/03/2024
ALK ( ALKB:DC / OMX: ALK B / AKBLF ): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions [...]
H1 Recognized as One of Forbes’ Best Startup Employers in 2024
05/03/2024
Global healthcare intelligence platform placed among the top 500 U.S. companies from a long list of 20,000 NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- H1 , the leading source of truth for global healthcare [...]
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
05/03/2024
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an “Inflammation & [...]
USOSM Chief Operations and Chief Human Resources Officers to Speak at Women in DSO’s Empower and Grow Conference
05/03/2024
IRVING, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management (USOSM) Chief Operations Officer Alisa Ulrey and USOSM Chief Human Resources Officer Annette Igl will be panel speakers in the upcoming [...]
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
05/03/2024
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 9,798,000 [...]
One World Products Launches Pro-11 CBD-Enriched Performance Muscle Rub
05/03/2024
Introduced at the 2024 NBA All-Star Weekend on February 18, Direct-to-Consumer availability planned for March 15 LAS VEGAS, NV, March 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Today, One World Products, Inc. (" [...]
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
05/03/2024
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words LOS ANGELES, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “ [...]
Merit Medical to Host Evening of Innovation during the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
05/03/2024
Merit Medical to host SIR attendees at Salt Lake City headquarters and SIR booth 320 SOUTH JORDAN, Utah, March 05, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare [...]
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
05/03/2024
Shareholders approve 27 th consecutive dividend increase to CHF 3.30 (+ 3.1% ) per share for 2023; representing a 3.7% yield 1 and approximately 58% payout of free cash flow Shareholders confirm Joerg Reinhardt as Chair [...]
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
05/03/2024
Les actionnaires approuvent la 27 e augmentation consécutive du dividende qui passe à CHF 3,30 (+3,1%) par action pour 2023 ; représentant un rendement de 3,7% 1 et une distribution du free cash-flow d’environ 58% Les [...]

Pages